LVM Capital Management Ltd. MI Buys 8,576 Shares of Stryker Corporation $SYK

by · The Markets Daily

LVM Capital Management Ltd. MI grew its stake in Stryker Corporation (NYSE:SYK – Free Report) by 15.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,584 shares of the medical technology company’s stock after acquiring an additional 8,576 shares during the quarter. Stryker comprises about 1.6% of LVM Capital Management Ltd. MI’s portfolio, making the stock its 19th biggest position. LVM Capital Management Ltd. MI’s holdings in Stryker were worth $19,704,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the last quarter. State Street Corp raised its holdings in Stryker by 2.1% in the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after buying an additional 69,851 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Stryker in the 4th quarter valued at about $1,822,272,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of SYK stock opened at $345.05 on Tuesday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market cap of $132.35 billion, a PE ratio of 35.76, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The business has a 50-day simple moving average of $321.03 and a 200-day simple moving average of $333.81.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on SYK. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. JPMorgan Chase & Co. lowered their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. UBS Group started coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target on the stock. Piper Sandler reduced their price target on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, Wolfe Research set a $375.00 price objective on Stryker in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Check Out Our Latest Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).